Romana Ayub, Syed Shahmeer Raza, Irfan Ullah, Nayab Ahsan, Maryam Rauf, Saira Kainat Awan, Gulsam Bashir, Mahnoor Inamullah, Fatima Afaq, Syed Arsalan Ali Shah
Corona Virus Disease 2019 or more simply known as the COVID-19 emerged from the City of Wuhan in the Hubei Province of China in the last quarter of 2019 as cases presenting with pneumonia but unknown aetiology. COVID-19 presents with a wide range of clinical symptoms including Fever, Cough, Shortness of Breath (SOB), Headache and Muscle Pain Etc. Prevention is critical as there is no specific and approved treatment for COVID-19 at this time. Although many trials are underway, none has so far been very successful with a breakthrough in this regard. Treatment generally revolves around giving symptomatic and supportive care to control fever, hydration and nutrition. Different drugs including the use of Antivirals with or without a combination of antibiotics has been warranted but to no major success so far. Alternative options including the use of Passive immunization via monoclonal antibody therapy show progress but so far, the antibodies haven’t been marketed. The rise of neutrophils in the lungs and a serum elevated level of cytokines and chemokines responsible for inflammation is believed to be related to the lung damage seen in the COVID-19 patients. Presence of the SARS-CoV-2 viral antigen in the sample detected via the PCR or ELISA technique, confirms the diagnosis of COVID-19 Infection. COVID-19 has an economic fall out that most countries of the world now fear an economic recession due to the existing and extended lockdown imposed at the moment. Therefore, measures need to be taken to curb this before the situation gets out of hand, especially for developing countries.